Navigation Links
Weight-Loss Medication Evaluated By Nutrition Expert

A 60 mg low-dose version of the prescription weight-loss medication orlistat (marketed by GlaxoSmithKline as Xenical? 120 mg) was found to be safe, effective and tolerable in overweight individuals,// according to new data presented today at the 2005 Annual Meeting of NAASO, The Obesity Society in Vancouver, British Columbia.

The study, which compared orlistat 60 mg plus diet to placebo plus diet in patients with a body mass index (BMI) of 25 to 28, demonstrates a statistically significant difference in weight loss. Orlistat patients who completed the four-month treatment period lost 5 percent of their baseline weight and diet alone lost 3.3 percent.

The randomized, placebo-controlled, 16-week study was conducted in a primary care setting, offered minimal intervention and was largely self-instructional. Approximately 36 percent of orlistat users and 28 percent of the placebo group (who used diet modifications alone) lost more than five percent of their initial body weight. Approximately 57 percent of orlistat users, compared to 42 percent of the placebo group, lost more than three percent of their initial body weight.

Orlistat patients also demonstrated significant decreases in total cholesterol, LDL cholesterol, systolic and diastolic blood pressure. Safety and tolerability of 60 mg orlistat in this population was similar to that observed in previous studies in a more overweight population.

"Prescription orlistat has been used successfully for years to help obese individuals lose weight and improve their health, so it's exciting to find that a lower dose of orlistat can help those who are overweight with their weight loss efforts," said lead investigator Dr. James Anderson, Professor of Medicine and Clinical Nutrition at the University of Kentucky. "The number of overweight individuals in this country continues to increase each year, and the risk of these folks progressing to obesity - and the resulting more serious med ical problems - is significant."
'"/>




Related medicine news :

1. Weight-Loss Drinks Can Make You Gassy
2. Weight-Loss Surgeries Changing Lives
3. Latest Weight-Loss Pill Offers Modest Results, Blocks Munchies
4. Weight-Loss Drugs – Will They also Make You Lose Sleep
5. What happens when Medications go wrong?
6. Medications to Prevent Relapse to Cocaine Use
7. More Elderly Take Inappropriate and Harmful Medications
8. Medications for depression
9. Medications linked to xerostomia and caries
10. Medication recuperates fat distribution in diabetes
11. Pharmacist’s Role in Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... OR (PRWEB) , ... February 05, 2016 , ... The ... modern technology, such water may be safer than regular municipal or well water. The ... and radio host Sharon Kleyne, could go a long way toward increasing public acceptance ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting ... McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA ... Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... inaugural Columbia University Men’s Soccer Career Development event in New York City on ... Rocco Commisso, Chairman and CEO of Mediacom, (both alumnus of the varsity Columbia ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
Breaking Medicine Technology: